Internal Medicine Evidence

Description:

Increase your knowledge of the clinical trials and evidence that lay the groundwork for current practice with Internal Medicine Evidence: The Practice-Changing Studies. Brief, easy-to-read, and accessible, this time-saving reference allows you to quickly familiarize yourself with 100 of the most practice-changing clinical trials in internal medicine. This unique title is ideal for medical students, residents, and seasoned practitioners alike, providing insight and understanding into today’s practice of internal medicine.

Table of Contents:

SECTION 1: CARDIOLOGY

1. Rate Versus Rhythm Control in Atrial Fibrillation: The AFFIRM Trial

2. Angioplasty Versus Streptokinase in Myocardial Infarction

3. First-Step Antihypertensive Therapy: The ALLHAT Trial

4. Heart Failure Treatment for African Americans: The A-HeFT Trial

5. Dual Antiplatelet Therapy in Non–ST-Elevation ACS: The CURE Trial

6. ACE Inhibitors in Congestive Heart Failure: The CONSENSUS Trial

7. CRT in Advanced Heart Failure: The COMPANION Trial

8. Beta Blockers in Chronic Heart Failure: The COMET Trial

9. Antiplatelet Therapy for Preventing Vascular Events

10. Statin Therapy After ACS: PROVE IT-TIMI 22

11. Transcatheter Aortic Valve Implantation: The PARTNER B Trial

12. Angioplasty Versus t-PA in Myocardial Infarction: The PAMI-1 Study

13. Aspirin and Thrombolysis in Myocardial Infarction: The ISIS-2 Trial

14. Heparin in ACS without ST Elevation

15. PCI Versus CABG for Severe CAD: The SYNTAX Trial

16. Antiarrhythmics and ICDs in CHF: The SCD-HeFT Trial

17. ACE Inhibitors in LV Dysfunction: The SAVE Trial

18. Dabigatran for Atrial Fibrillation: The RE-LY Trial

19. Spironolactone in Severe HF: The RALES Trial

20. Cholesterol Lowering in Coronary Artery Disease: The 4S Trial

SECTION 2: CRITICAL CARE

21. Glucose Control in ICU Patients: The NICE-SUGAR Trial

22. Therapeutic Hypothermia after Cardiac Arrest: The HACA Trial

23. Corticosteroids in Septic Shock: The CORTICUS Trial

24. Low Tidal Volume Ventilation for Acute Respiratory Distress Syndrome: The ARMA Trial

25. Timing of Antibiotics in Septic Shock

26. Paired Weaning Protocol for Mechanical Ventilation and Sedation: The ABC Trial

27. Blood Transfusion for ICU Patients: The TRICC Trial

28. Choice of First Vasopressor in Shock: The SOAP II Trial

29. Revascularization for Cardiogenic Shock after Myocardial Infarction: The SHOCK Trial

30. Early Goal-Directed Therapy in Sepsis

31. Prone Positioning in Severe ARDS: The PROSEVA Trial

SECTION 3: ENDOCRINOLOGY

32. ACE Inhibitors for Diabetic Nephropathy

33. Bisphosphonates and Fracture Risk: The FIT Trial

34. Insulin Therapy and Diabetes Complications: The DCCT Trial

35. Hormone Replacement Therapy in Postmenopausal Women: The Women’s Health Initiative (WHI) Trial

36. Lifestyle Intervention and Metformin in Diabetes: The DPP Study

SECTION 4: GASTROENTEROLOGY

37. Antibiotics in Variceal GI Bleeding

38. Transfusion in UGIB

39. PPI Before Endoscopy in UGIB

40. Albumin in SBP

41. 10-Year Interval for Screening Colonoscopy

42. SAAG in the Diagnosis of Ascites

43. Rifaximin in Hepatic Encephalopathy

44. “Top-Down” Therapy for Crohn Disease

SECTION 5: HEMATOLOGY

45. Plasma Exchange in Thrombotic Thrombocytopenic Purpura

46. Natural History and Prognosis of MGUS

47. The JAK2 Mutation in Myeloproliferative Neoplasms

48. Imatinib for CML

49. R-CHOP for Diffuse Large B-Cell Lymphoma: The GELA Trial

50. HiDAC as Consolidation Therapy for AML

51. ATRA Versus Chemotherapy for Acute Promyelocytic Leukemia

52. Bortezomib in Relapsed Multiple Myeloma: The APEX Trial

53. Optimal Therapy after First Complete Remission in AML

54. Genotype for Risk Stratification in Acute Myeloid Leukemia

SECTION 6: INFECTIOUS DISEASES

55. ART for Early Asymptomatic HIV: The START Study

56. Direct Acting Antivirals for HCV: The NEUTRINO and FISSION Trials

57. Antibiotic Monotherapy for Febrile Neutropenia

58. HIV Pre-exposure Chemoprophylaxis: The iPrEx Study

59. Oral Vancomycin for Severe C. difficile Infections

60. SMX-TMP for PCP Prophylaxis in AIDS

61. Combination ART for HIV

62. Early ART to Prevent HIV Transmission

63. Timing of ART with Acute OIs in HIV

64. Oseltamivir for Influenza

SECTION 7: NEPHROLOGY

65. Intensity of Renal Replacement Therapy in the ICU

66. ACE Inhibitors in Chronic Nondiabetic Nephropathy: The REIN Trial

67. The MDRD Equation to Estimate GFR

68. High-Dose and High-Flux Membrane Use in Hemodialysis: The HEMO Study

69. Use of EPO in CKD: The CHOIR Trial

70. Renal Transplant Induction Regimen

SECTION 8: ONCOLOGY

71. Prostatectomy Versus Watchful Waiting for Low-Risk Prostate Cancer: The SPCG-4 Trial

72. Low-Dose CT for Lung Cancer Screening: The NLST

73. Oxaliplatin as Adjuvant Therapy in Colon Cancer: The MOSAIC Trial

74. EGFR Inhibition in Non–Small-Cell Lung Cancer: The IPASS Trial

75. HER2-Targeted Therapy in Breast Cancer

76. Polypectomy to Prevent Colorectal Cancer: The National Polyp Study

77. Prevention of Recurrent VTE with LMWH in Patients with Cancer: The CLOT Trial

78. Breast-Conserving Surgery for Early Breast Cancer

79. Bevacizumab in Metastatic Colorectal Cancer Treatment

80. Aromatase Inhibitors in Early Breast Cancer

SECTION 9: PULMONOLOGY

81. The Wells Score for Pulmonary Embolism

82. Vena Caval Filters: The PREPIC Trial

83. Thrombolysis in Acute Pulmonary Embolism

84. Combination Long-Acting Beta Agonist and Inhaled Corticosteroid in COPD: The TORCH Trial

85. Dabigatran for the Treatment of Venous Thromboembolism: The RE-COVER Trial

86. Noninvasive Ventilation for COPD Exacerbations

87. LMWH for VTE Prophylaxis: The MEDENOX Trial

88. Light’s Criteria for Pleural Effusions

89. Long-Acting Muscarinic Therapy in COPD

90. Inhaled Corticosteroids in COPD

91. Glucocorticoids for COPD Exacerbations

92. Dual Therapy in Asthma: The FACET Study

93. Targeting Molecular Defects in Cystic Fibrosis

94. Pirfenidone in IPF: The ASCEND Trial

95. Antibiotics in COPD Exacerbations

SECTION 10: RHEUMATOLOGY

96. Anti-TNFα Therapy in Rheumatoid Arthritis

97. Treatment of ANCA-Associated Vasculitis: The RAVE Trial

98. Hydroxychloroquine in SLE

99. Treatment Strategies in RA: The BeSt Study

100. Induction Treatment for Lupus Nephritis: The ALMS Trial

Index

Read Less